Cargando…
Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65
Leber congenital amaurosis is a group of inherited retinal dystrophies that cause severe sight impairment in childhood; RPE65-deficiency causes impaired rod photoreceptor function from birth and progressive impairment of cone photoreceptor function associated with retinal degeneration. In animal mod...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143366/ https://www.ncbi.nlm.nih.gov/pubmed/27653967 http://dx.doi.org/10.1038/gt.2016.66 |
_version_ | 1782472925652189184 |
---|---|
author | Georgiadis, A Duran, Y Ribeiro, J Abelleira-Hervas, L Robbie, S J Sünkel-Laing, B Fourali, S Gonzalez-Cordero, A Cristante, E Michaelides, M Bainbridge, J W B Smith, A J Ali, R R |
author_facet | Georgiadis, A Duran, Y Ribeiro, J Abelleira-Hervas, L Robbie, S J Sünkel-Laing, B Fourali, S Gonzalez-Cordero, A Cristante, E Michaelides, M Bainbridge, J W B Smith, A J Ali, R R |
author_sort | Georgiadis, A |
collection | PubMed |
description | Leber congenital amaurosis is a group of inherited retinal dystrophies that cause severe sight impairment in childhood; RPE65-deficiency causes impaired rod photoreceptor function from birth and progressive impairment of cone photoreceptor function associated with retinal degeneration. In animal models of RPE65 deficiency, subretinal injection of recombinant adeno-associated virus (AAV) 2/2 vectors carrying RPE65 cDNA improves rod photoreceptor function, and intervention at an early stage of disease provides sustained benefit by protecting cone photoreceptors against retinal degeneration. In affected humans, administration of these vectors has resulted to date in relatively modest improvements in photoreceptor function, even when retinal degeneration is comparatively mild, and the duration of benefit is limited by progressive retinal degeneration. We conclude that the demand for RPE65 in humans is not fully met by current vectors, and predict that a more powerful vector will provide more durable benefit. With this aim we have modified the original AAV2/2 vector to generate AAV2/5-OPTIRPE65. The new configuration consists of an AAV vector serotype 5 carrying an optimized hRPE65 promoter and a codon-optimized hRPE65 gene. In mice, AAV2/5-OPTIRPE65 is at least 300-fold more potent than our original AAV2/2 vector. |
format | Online Article Text |
id | pubmed-5143366 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51433662016-12-23 Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 Georgiadis, A Duran, Y Ribeiro, J Abelleira-Hervas, L Robbie, S J Sünkel-Laing, B Fourali, S Gonzalez-Cordero, A Cristante, E Michaelides, M Bainbridge, J W B Smith, A J Ali, R R Gene Ther Short Communication Leber congenital amaurosis is a group of inherited retinal dystrophies that cause severe sight impairment in childhood; RPE65-deficiency causes impaired rod photoreceptor function from birth and progressive impairment of cone photoreceptor function associated with retinal degeneration. In animal models of RPE65 deficiency, subretinal injection of recombinant adeno-associated virus (AAV) 2/2 vectors carrying RPE65 cDNA improves rod photoreceptor function, and intervention at an early stage of disease provides sustained benefit by protecting cone photoreceptors against retinal degeneration. In affected humans, administration of these vectors has resulted to date in relatively modest improvements in photoreceptor function, even when retinal degeneration is comparatively mild, and the duration of benefit is limited by progressive retinal degeneration. We conclude that the demand for RPE65 in humans is not fully met by current vectors, and predict that a more powerful vector will provide more durable benefit. With this aim we have modified the original AAV2/2 vector to generate AAV2/5-OPTIRPE65. The new configuration consists of an AAV vector serotype 5 carrying an optimized hRPE65 promoter and a codon-optimized hRPE65 gene. In mice, AAV2/5-OPTIRPE65 is at least 300-fold more potent than our original AAV2/2 vector. Nature Publishing Group 2016-12 2016-09-22 /pmc/articles/PMC5143366/ /pubmed/27653967 http://dx.doi.org/10.1038/gt.2016.66 Text en Copyright © 2016 The Author(s) https://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Short Communication Georgiadis, A Duran, Y Ribeiro, J Abelleira-Hervas, L Robbie, S J Sünkel-Laing, B Fourali, S Gonzalez-Cordero, A Cristante, E Michaelides, M Bainbridge, J W B Smith, A J Ali, R R Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 |
title | Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 |
title_full | Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 |
title_fullStr | Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 |
title_full_unstemmed | Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 |
title_short | Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 |
title_sort | development of an optimized aav2/5 gene therapy vector for leber congenital amaurosis owing to defects in rpe65 |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143366/ https://www.ncbi.nlm.nih.gov/pubmed/27653967 http://dx.doi.org/10.1038/gt.2016.66 |
work_keys_str_mv | AT georgiadisa developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT durany developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT ribeiroj developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT abelleirahervasl developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT robbiesj developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT sunkellaingb developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT fouralis developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT gonzalezcorderoa developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT cristantee developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT michaelidesm developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT bainbridgejwb developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT smithaj developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 AT alirr developmentofanoptimizedaav25genetherapyvectorforlebercongenitalamaurosisowingtodefectsinrpe65 |